Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Synchrotope TA2M

Vaccine · Immune activation · developed by Mannkind

Phase 1 Most advanced trial (none active)
MNKD Developer
1 Registered trials

What is Synchrotope TA2M?

Synchrotope TA2M is a cancer vaccine given with immunotherapy, studied in melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Mechanism
Immune activation
Therapy area
Oncology
Developer
Mannkind Corporation (MNKD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00023647 Phase 1 Melanoma (Skin) Completed MNKD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Melanoma (Skin)

More from Mannkind

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MNKD page.

Follow MNKD, the company behind Synchrotope TA2M

See MNKD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MNKD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.